Tourmaline Bio, Inc. announced its first quarter 2025 financial results, highlighting its ongoing Phase 2 TRANQUILITY trial which is set to reveal topline data in the second quarter of 2025. The trial ...
Tourmaline has reported positive net income since 2017, reflecting its ability to generate profits even when gas prices are low. Over the next five years, the company anticipates increasing its ...
Tourmaline Bio, Inc. announced its fourth-quarter and full-year financial results for 2024, highlighting significant progress in its clinical development programs, particularly the Phase 2 TRANQUILITY ...
The last time I spoke about Tourmaline Bio (TRML) it was with respect to a Seeking Alpha article entitled "Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting." In this article, I ...
Those following along with Tourmaline Oil Corp. ( TSE:TOU ) will no doubt be intrigued by the recent purchase of ...
Tourmaline Oil Corp. (TRMLF) came out with quarterly earnings of $0.39 per share, missing the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $0.51 per share a year ago.
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. A vividly colored slice of Maine watermelon tourmaline at the Maine Mineral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results